Ranok Therapeutics secured clearance from the US Food and Drug Administration (FDA) to stage a Phase I/II trial for its RNK05047 to treat advanced solid tumours and lymphomas.

Ranok anticipates commencing subject enrolment in the Phase I/II CHAMP-1 trial in the first half of this year.

Discovered and developed using the Chaperone-mediated Protein Degradation (CHAMP) platform of the company, RNK05047 is a small-molecule, BRD4-selective protein degrader.

Using Ranok’s capabilities in protein homeostasis and cellular chaperone network, the technology is claimed to degrade disease-linked proteins. 

Cellular chaperone network controls the proteins’ folding and stability.

Furthermore, CHAMP could boost the safety and efficacy of the drug by specifically acting on disease tissues, the company noted.

Ranok founder and CEO Weiwen Ying said: “We are looking forward to initiating this clinical study of the first small-molecule therapy based on our CHAMP platform technology.

“The bromodomain transcription factor BRD4 is a master regulator of oncogenes involved in diverse cancer types. RNK05047 is designed to selectively degrade BRD4 protein in a tumour-targeted fashion, which differentiates it from other investigational therapies.”

In November last year, the company signed an agreement with Pfizer to use and assess CHAMP platform technology on an undisclosed cancer target. 

The companies have not divulged the terms of the deal.

Ranok raised $40m in a Series B financing round led by Lapam Capital and Shanghai Healthcare Capital in August last year. It has raised funds worth more than $50m.

The funding will be used to support the continued development of advanced cancer programme and to extend its preclinical pipeline of new treatments that are based on the CHAMP platform.